ID

14969

Description

Metronomic Poly-chemotherapy for Metastatic CRC; ODM derived from: https://clinicaltrials.gov/show/NCT02280694

Link

https://clinicaltrials.gov/show/NCT02280694

Keywords

Versions (1)
  1. 5/10/16 5/10/16 -
Uploaded on

May 10, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Cancer NCT02280694

English

Eligibility Colorectal Cancer NCT02280694

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histological (or cytological) proof of colorectal carcinoma (crc)
Description

Colorectal Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0009402
2. measurable metastases
Description

Neoplasm Metastasis Measurable

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1513040
3. ecog (eastern cooperative oncology group) performance status 0-2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
4. progressing disease following all available chemotherapy treatment lines (including chemotherapy, bevacizumab+/-ziv-aflibercept, and an epidermal growth factor receptor (egfr) inhibitor [if wt(wild type)-kras]
Description

Progressive Neoplastic Disease | Chemotherapy Regimen | bevacizumab | ziv-aflibercept | Epidermal growth factor receptor inhibitor | KRAS wt Allele

Data type

boolean

Alias
UMLS CUI [1]
C0677932
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0796392
UMLS CUI [4]
C3485619
UMLS CUI [5]
C1443775
UMLS CUI [6]
C1705982
5. the central-radiologist's confirmation of pd* under the last (previous) line of "conventional treatment" and determination of pfs1, according to recist criteria
Description

Progressive Neoplastic Disease | Progression-Free Survival | Response Evaluation Criteria in Solid Tumors

Data type

boolean

Alias
UMLS CUI [1]
C0677932
UMLS CUI [2]
C0242792
UMLS CUI [3]
C1709926
pd (progressive disease) by recist(response evaluation criteria in solid tumors) criteria : a) there is 20% or more relative increment in the sum of diameters of target lesions in comparison with the base line sum, and their absolute increase is 5 mm. or more, or b) there appeared one or more new lesions, or c)there is substantial worsening in non-target disease
Description

Progressive Neoplastic Disease Response Evaluation Criteria in Solid Tumors | Target Lesion Identification | Increment Relative | Increase Absolute | New Lesion Identification | Non-Target Lesion Identification Worsening

Data type

boolean

Alias
UMLS CUI [1,1]
C0677932
UMLS CUI [1,2]
C1709926
UMLS CUI [2]
C2986546
UMLS CUI [3,1]
C1705117
UMLS CUI [3,2]
C0205345
UMLS CUI [4,1]
C0442805
UMLS CUI [4,2]
C0205344
UMLS CUI [5]
C2986548
UMLS CUI [6,1]
C2986547
UMLS CUI [6,2]
C0332271
6. age: between 18 and 85
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
7. prior radiotherapy either as adjuvant treatment or for palliation is allowed, unless this was delivered to the only measurable lesion
Description

prior radiation therapy Adjuvant therapy | Palliative course of radiotherapy | Measurable lesion

Data type

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0677850
UMLS CUI [2]
C0475092
UMLS CUI [3]
C1513041
8. complete blood counts showing normal values or any toxicity limited to grade 1.
Description

Full blood count normal | Mild Adverse Event

Data type

boolean

Alias
UMLS CUI [1]
C0427692
UMLS CUI [2]
C1513302
9. blood chemistry tests showing liver and renal functions < 1.5 upper normal limit (unl)
Description

Whole Blood Chemistry Test | Liver function | Renal function | Upper Limit of Normal

Data type

boolean

Alias
UMLS CUI [1]
C1254486
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
UMLS CUI [4]
C1519815
10. absence of any non-hematological toxicity at grade 2 or higher
Description

Adverse Event Toxicity Grade Mild Adverse Event

Data type

boolean

Alias
UMLS CUI [1,1]
C2697890
UMLS CUI [1,2]
C1513302
11. the experimental treatment should start within 3 to 7 weeks from the last cycle of conventional treatment
Description

Therapies, Investigational | Conventional Treatment

Data type

boolean

Alias
UMLS CUI [1]
C0949266
UMLS CUI [2]
C2945704
12. the patient is able to understand and ready to sign the informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. lack of confirmation of pd (under the pre-study treatment) by the central radiologist
Description

Lacking Confirmation of Progressive Neoplastic Disease

Data type

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C0521091
UMLS CUI [1,3]
C0677932
2. any concurrent other active cancer (except basal cell or squamous cell carcinoma of skin and early prostate cancer or dcis- in situ breast cancer)
Description

Malignant Neoplasms Concurrent | Basal cell carcinoma | Squamous cell carcinoma of skin | prostate cancer screening | Noninfiltrating Intraductal Carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205420
UMLS CUI [2]
C0007117
UMLS CUI [3]
C0553723
UMLS CUI [4]
C0281186
UMLS CUI [5]
C0007124
3. inability to adhere to monthly visits to the oncological unit for evaluation
Description

Unable Patient Visit Monthly

Data type

boolean

Alias
UMLS CUI [1,1]
C1299582
UMLS CUI [1,2]
C1512346
UMLS CUI [1,3]
C0332177
4. presence of brain metastases
Description

Metastatic malignant neoplasm to brain

Data type

boolean

Alias
UMLS CUI [1]
C0220650
5. continuous treatment with steroids or with nsaids or with anticoagulants during the last year (except micropirin)
Description

Therapeutic procedure | Steroids | Anti-Inflammatory Agents, Non-Steroidal | Anticoagulants | Nu-Seals Aspirin

Data type

boolean

Alias
UMLS CUI [1]
C0087111
UMLS CUI [2]
C0038317
UMLS CUI [3]
C0003211
UMLS CUI [4]
C0003280
UMLS CUI [5]
C0591883
6. previous radiotherapy to the only site of measurable disease
Description

prior radiation therapy Measurable Disease Site

Data type

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C1513041
UMLS CUI [1,3]
C0205145
7. existence of active peptic ulcer or symptomatic coronary disease
Description

Peptic Ulcer | Coronary heart disease

Data type

boolean

Alias
UMLS CUI [1]
C0030920
UMLS CUI [2]
C0010068
8. existence of chronic inflammatory diseases, such as ulcerative colitis or crohn's disease or rheumatoid arthritis
Description

Chronic inflammatory disorder | Ulcerative Colitis | Crohn Disease | Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C1290886
UMLS CUI [2]
C0009324
UMLS CUI [3]
C0010346
UMLS CUI [4]
C0003873
9. presence of ascites, and/or any other "third space" finding (eg. significant leg edema)
Description

Ascites | Leg edema

Data type

boolean

Alias
UMLS CUI [1]
C0003962
UMLS CUI [2]
C0235886
Back to the top of the page

Similar models

Eligibility Colorectal Cancer NCT02280694

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Colorectal Carcinoma
Item
1. histological (or cytological) proof of colorectal carcinoma (crc)
boolean
C0009402 (UMLS CUI [1])
Neoplasm Metastasis Measurable
Item
2. measurable metastases
boolean
C0027627 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
ECOG performance status
Item
3. ecog (eastern cooperative oncology group) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Progressive Neoplastic Disease | Chemotherapy Regimen | bevacizumab | ziv-aflibercept | Epidermal growth factor receptor inhibitor | KRAS wt Allele
Item
4. progressing disease following all available chemotherapy treatment lines (including chemotherapy, bevacizumab+/-ziv-aflibercept, and an epidermal growth factor receptor (egfr) inhibitor [if wt(wild type)-kras]
boolean
C0677932 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C3485619 (UMLS CUI [4])
C1443775 (UMLS CUI [5])
C1705982 (UMLS CUI [6])
Progressive Neoplastic Disease | Progression-Free Survival | Response Evaluation Criteria in Solid Tumors
Item
5. the central-radiologist's confirmation of pd* under the last (previous) line of "conventional treatment" and determination of pfs1, according to recist criteria
boolean
C0677932 (UMLS CUI [1])
C0242792 (UMLS CUI [2])
C1709926 (UMLS CUI [3])
Progressive Neoplastic Disease Response Evaluation Criteria in Solid Tumors | Target Lesion Identification | Increment Relative | Increase Absolute | New Lesion Identification | Non-Target Lesion Identification Worsening
Item
pd (progressive disease) by recist(response evaluation criteria in solid tumors) criteria : a) there is 20% or more relative increment in the sum of diameters of target lesions in comparison with the base line sum, and their absolute increase is 5 mm. or more, or b) there appeared one or more new lesions, or c)there is substantial worsening in non-target disease
boolean
C0677932 (UMLS CUI [1,1])
C1709926 (UMLS CUI [1,2])
C2986546 (UMLS CUI [2])
C1705117 (UMLS CUI [3,1])
C0205345 (UMLS CUI [3,2])
C0442805 (UMLS CUI [4,1])
C0205344 (UMLS CUI [4,2])
C2986548 (UMLS CUI [5])
C2986547 (UMLS CUI [6,1])
C0332271 (UMLS CUI [6,2])
Age
Item
6. age: between 18 and 85
boolean
C0001779 (UMLS CUI [1])
prior radiation therapy Adjuvant therapy | Palliative course of radiotherapy | Measurable lesion
Item
7. prior radiotherapy either as adjuvant treatment or for palliation is allowed, unless this was delivered to the only measurable lesion
boolean
C0279134 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0475092 (UMLS CUI [2])
C1513041 (UMLS CUI [3])
Full blood count normal | Mild Adverse Event
Item
8. complete blood counts showing normal values or any toxicity limited to grade 1.
boolean
C0427692 (UMLS CUI [1])
C1513302 (UMLS CUI [2])
Whole Blood Chemistry Test | Liver function | Renal function | Upper Limit of Normal
Item
9. blood chemistry tests showing liver and renal functions < 1.5 upper normal limit (unl)
boolean
C1254486 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C1519815 (UMLS CUI [4])
Adverse Event Toxicity Grade Mild Adverse Event
Item
10. absence of any non-hematological toxicity at grade 2 or higher
boolean
C2697890 (UMLS CUI [1,1])
C1513302 (UMLS CUI [1,2])
Therapies, Investigational | Conventional Treatment
Item
11. the experimental treatment should start within 3 to 7 weeks from the last cycle of conventional treatment
boolean
C0949266 (UMLS CUI [1])
C2945704 (UMLS CUI [2])
Informed Consent
Item
12. the patient is able to understand and ready to sign the informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Lacking Confirmation of Progressive Neoplastic Disease
Item
1. lack of confirmation of pd (under the pre-study treatment) by the central radiologist
boolean
C0332268 (UMLS CUI [1,1])
C0521091 (UMLS CUI [1,2])
C0677932 (UMLS CUI [1,3])
Malignant Neoplasms Concurrent | Basal cell carcinoma | Squamous cell carcinoma of skin | prostate cancer screening | Noninfiltrating Intraductal Carcinoma
Item
2. any concurrent other active cancer (except basal cell or squamous cell carcinoma of skin and early prostate cancer or dcis- in situ breast cancer)
boolean
C0006826 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C0007117 (UMLS CUI [2])
C0553723 (UMLS CUI [3])
C0281186 (UMLS CUI [4])
C0007124 (UMLS CUI [5])
Unable Patient Visit Monthly
Item
3. inability to adhere to monthly visits to the oncological unit for evaluation
boolean
C1299582 (UMLS CUI [1,1])
C1512346 (UMLS CUI [1,2])
C0332177 (UMLS CUI [1,3])
Metastatic malignant neoplasm to brain
Item
4. presence of brain metastases
boolean
C0220650 (UMLS CUI [1])
Therapeutic procedure | Steroids | Anti-Inflammatory Agents, Non-Steroidal | Anticoagulants | Nu-Seals Aspirin
Item
5. continuous treatment with steroids or with nsaids or with anticoagulants during the last year (except micropirin)
boolean
C0087111 (UMLS CUI [1])
C0038317 (UMLS CUI [2])
C0003211 (UMLS CUI [3])
C0003280 (UMLS CUI [4])
C0591883 (UMLS CUI [5])
prior radiation therapy Measurable Disease Site
Item
6. previous radiotherapy to the only site of measurable disease
boolean
C0279134 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C0205145 (UMLS CUI [1,3])
Peptic Ulcer | Coronary heart disease
Item
7. existence of active peptic ulcer or symptomatic coronary disease
boolean
C0030920 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
Chronic inflammatory disorder | Ulcerative Colitis | Crohn Disease | Rheumatoid Arthritis
Item
8. existence of chronic inflammatory diseases, such as ulcerative colitis or crohn's disease or rheumatoid arthritis
boolean
C1290886 (UMLS CUI [1])
C0009324 (UMLS CUI [2])
C0010346 (UMLS CUI [3])
C0003873 (UMLS CUI [4])
Ascites | Leg edema
Item
9. presence of ascites, and/or any other "third space" finding (eg. significant leg edema)
boolean
C0003962 (UMLS CUI [1])
C0235886 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial